Ross Muken
Stock Analyst at Evercore ISI Group
(2.22)
# 2,635
Out of 4,711 analysts
43
Total ratings
57.14%
Success rate
4.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ross Muken
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Maintains: In-Line | $190 → $225 | $185.77 | +21.12% | 6 | Nov 7, 2024 | |
| PDCO Patterson Companies | Maintains: In-Line | $23 → $22 | $30.86 | -28.71% | 3 | Oct 8, 2024 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $360 → $350 | $207.51 | +68.67% | 7 | Oct 8, 2024 | |
| HSIC Henry Schein | Maintains: In-Line | $70 → $74 | $69.82 | +5.99% | 8 | Oct 8, 2024 | |
| A Agilent Technologies | Maintains: In-Line | $126 → $130 | $134.51 | -3.35% | 11 | Jul 2, 2024 | |
| QGEN Qiagen | Downgrades: In-Line | n/a | $44.67 | - | 2 | Jul 16, 2019 | |
| CAH Cardinal Health | Initiates: In-Line | $67 | $118.28 | -43.35% | 2 | Jan 5, 2018 | |
| ILMN Illumina | Initiates: Outperform | $250 | $136.02 | +83.80% | 2 | Jan 4, 2018 | |
| TMO Thermo Fisher | Initiates: Outperform | $220 | $524.05 | -58.02% | 1 | Jan 4, 2018 | |
| MBLY Mobileye | Downgrades: In-Line | n/a | $17.51 | - | 1 | Mar 13, 2017 |
Charles River Laboratories International
Nov 7, 2024
Maintains: In-Line
Price Target: $190 → $225
Current: $185.77
Upside: +21.12%
Patterson Companies
Oct 8, 2024
Maintains: In-Line
Price Target: $23 → $22
Current: $30.86
Upside: -28.71%
ICON Public Limited Company
Oct 8, 2024
Maintains: Outperform
Price Target: $360 → $350
Current: $207.51
Upside: +68.67%
Henry Schein
Oct 8, 2024
Maintains: In-Line
Price Target: $70 → $74
Current: $69.82
Upside: +5.99%
Agilent Technologies
Jul 2, 2024
Maintains: In-Line
Price Target: $126 → $130
Current: $134.51
Upside: -3.35%
Qiagen
Jul 16, 2019
Downgrades: In-Line
Price Target: n/a
Current: $44.67
Upside: -
Cardinal Health
Jan 5, 2018
Initiates: In-Line
Price Target: $67
Current: $118.28
Upside: -43.35%
Illumina
Jan 4, 2018
Initiates: Outperform
Price Target: $250
Current: $136.02
Upside: +83.80%
Thermo Fisher
Jan 4, 2018
Initiates: Outperform
Price Target: $220
Current: $524.05
Upside: -58.02%
Mobileye
Mar 13, 2017
Downgrades: In-Line
Price Target: n/a
Current: $17.51
Upside: -